Pharmigene, Inc.(TW:7595)
NT$8.34+0.54 (+2.96%)
TW:7595
Pharmigene, Inc. financials statements
NT$8.34
At close:+0.54 (+2.96%)
Pharmigene, Inc. (7595) Ratios
Pharmigene, Inc. Ratios
TW:7595's free cash flow for Q2 2026 was NT$23.63M. For the 2026 fiscal year, TW:7595's free cash flow was decreased by NT$-811.00K and operating cash flow was NT$24.45M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.58 | 4.77 | 6.92 | 6.75 | 11.52 |
| Quick Ratio | 1.26 | 3.74 | 6.17 | 6.00 | 10.76 |
| Cash Ratio | 0.41 | 1.76 | 1.87 | 2.01 | 4.20 |
| Solvency Ratio | -0.07 | -0.09 | -0.08 | -0.52 | -0.22 |
| Operating Cash Flow Ratio | -0.48 | -0.85 | -2.11 | -0.61 | -0.78 |
| Short-Term Operating Cash Flow Coverage | -0.80 | -3.46 | 38.50 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ -490.93M | NT$ -403.83M | NT$ -348.87M | NT$ 214.02M | NT$ 249.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.66 | 0.61 | 0.55 | 0.02 | 0.04 |
| Debt-to-Equity Ratio | 2.35 | 1.77 | 1.29 | 0.03 | 0.04 |
| Debt-to-Capital Ratio | 0.70 | 0.64 | 0.56 | 0.03 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.67 | 0.63 | 0.56 | 0.00 | 0.00 |
| Financial Leverage Ratio | 3.55 | 2.87 | 2.36 | 1.13 | 1.10 |
| Debt Service Coverage Ratio | -0.30 | -1.87 | -7.10 | -108.48 | -21.16 |
| Interest Coverage Ratio | -3.80 | -6.72 | -7.48 | -218.97 | -74.06 |
| Debt to Market Cap | 1.31 | 0.85 | 0.58 | 0.00 | 0.00 |
| Interest Debt Per Share | 13.30 | 12.46 | 12.75 | 0.22 | 0.35 |
| Net Debt to EBITDA | -20.46 | -11.21 | -12.01 | 3.06 | 13.11 |
| Profitability Margins | |||||
| Gross Profit Margin | 19.47% | 35.59% | 32.06% | 33.43% | 35.60% |
| EBIT Margin | -27.49% | -60.69% | -48.77% | -31.22% | -18.14% |
| EBITDA Margin | -14.64% | -40.12% | -31.54% | -16.45% | -5.28% |
| Operating Profit Margin | -27.49% | -69.75% | -44.60% | -33.22% | -17.58% |
| Pretax Profit Margin | -36.50% | -71.08% | -54.73% | -31.92% | -18.38% |
| Net Profit Margin | -36.52% | -71.11% | -54.74% | -31.93% | -18.12% |
| Continuous Operations Profit Margin | -36.52% | -71.11% | -54.74% | -31.93% | -18.12% |
| Net Income Per EBT | 100.03% | 100.04% | 100.02% | 100.03% | 98.58% |
| EBT Per EBIT | 132.78% | 101.91% | 122.72% | 96.07% | 104.56% |
| Return on Assets (ROA) | -7.39% | -8.26% | -6.94% | -11.12% | -5.59% |
| Return on Equity (ROE) | -26.22% | -23.74% | -16.36% | -12.57% | -6.13% |
| Return on Capital Employed (ROCE) | -6.47% | -8.55% | -5.86% | -12.85% | -5.77% |
| Return on Invested Capital (ROIC) | -5.88% | -8.40% | -5.83% | -12.65% | -5.59% |
| Return on Tangible Assets | -7.47% | -8.37% | -7.03% | -11.54% | -5.81% |
| Earnings Yield | -14.65% | -11.52% | -7.62% | -5.05% | -2.52% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.73 | 8.75 | 5.17 | 4.68 | 7.46 |
| Payables Turnover | 7.37 | 5.21 | 11.34 | 12.39 | 28.98 |
| Inventory Turnover | 3.64 | 1.40 | 3.29 | 3.12 | 4.45 |
| Fixed Asset Turnover | 0.37 | 0.20 | 0.24 | 4.35 | 3.52 |
| Asset Turnover | 0.20 | 0.12 | 0.13 | 0.35 | 0.31 |
| Working Capital Turnover Ratio | 1.44 | 0.56 | 0.61 | 0.56 | 0.45 |
| Cash Conversion Cycle | 148.60 | 232.64 | 149.49 | 165.57 | 118.27 |
| Days of Sales Outstanding | 97.81 | 41.73 | 70.57 | 77.96 | 48.90 |
| Days of Inventory Outstanding | 100.28 | 261.03 | 111.10 | 117.08 | 81.97 |
| Days of Payables Outstanding | 49.50 | 70.12 | 32.18 | 29.47 | 12.60 |
| Operating Cycle | 198.09 | 302.75 | 181.66 | 195.04 | 130.86 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.33 | -0.89 | -1.71 | -0.54 | -0.44 |
| Free Cash Flow Per Share | -1.52 | -2.22 | -16.42 | -0.78 | -0.87 |
| Dividend Paid and CapEx Coverage Ratio | -7.12 | -0.67 | -0.12 | -2.22 | -1.03 |
| Capital Expenditure Coverage Ratio | -7.12 | -0.67 | -0.12 | -2.22 | -1.03 |
| Operating Cash Flow Coverage Ratio | -0.10 | -0.07 | -0.14 | -2.49 | -1.31 |
| Operating Cash Flow to Sales Ratio | -0.34 | -0.38 | -0.58 | -0.18 | -0.15 |
| Free Cash Flow Yield | -15.33% | -15.55% | -78.17% | -4.03% | -4.08% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.83 | -8.69 | -13.13 | -19.85 | -39.63 |
| Price-to-Sales (P/S) Ratio | 2.49 | 6.17 | 7.18 | 6.32 | 7.19 |
| Price-to-Book (P/B) Ratio | 1.79 | 2.06 | 2.15 | 2.49 | 2.43 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -6.52 | -6.43 | -1.28 | -24.83 | -24.49 |
| Price-to-Operating Cash Flow Ratio | -7.44 | -16.04 | -12.30 | -36.03 | -48.18 |
| Price-to-Earnings Growth (PEG) Ratio | 0.59 | -3.48 | -0.21 | -0.24 | -0.62 |
| Enterprise Value Multiple | -37.49 | -26.59 | -34.79 | -35.35 | -123.02 |
| Enterprise Value | 1.10B | 1.24B | 1.46B | 777.97M | 840.60M |
| EV to EBITDA | -37.49 | -26.59 | -34.79 | -35.35 | -123.02 |
| EV to Sales | 5.49 | 10.67 | 10.97 | 5.81 | 6.50 |
| EV to Free Cash Flow | -14.36 | -11.12 | -1.95 | -22.85 | -22.14 |
| EV to Operating Cash Flow | -16.38 | -27.74 | -18.78 | -33.15 | -43.54 |
| Tangible Book Value Per Share | 5.31 | 6.65 | 9.47 | 7.49 | 8.43 |
| Shareholders’ Equity Per Share | 5.53 | 6.92 | 9.78 | 7.82 | 8.79 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | 0.01 |
| Revenue Per Share | 3.97 | 2.31 | 2.92 | 3.08 | 2.98 |
| Net Income Per Share | -1.45 | -1.64 | -1.60 | -0.98 | -0.54 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.99 |
| Interest Burden | 1.33 | 1.17 | 1.12 | 1.02 | 1.01 |
| Research & Development to Revenue | 0.20 | 0.25 | 0.23 | 0.22 | 0.12 |
| SG&A to Revenue | 0.36 | 0.80 | 0.54 | 0.44 | 0.42 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 0.54 | 1.07 | 0.55 | 0.81 |
Currency in TWD
